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1. Introduction 
Metabolomics were initially defined as the global analysis of all metabolites present in a 
sample (metabolomics) and the analysis of metabolic responses to drugs and diseases 
(metabonomics) [Nicholson et al., 1999, Fiehn 2002, Weckwerth and Morgenthal 2005]. 
These two definitions have an historical origin, while metabolomics has its foundations in 
microbial and plant sciences metabonomics originated in toxicology studies of mamalian 
systems. Today the two terms are becoming synonyms [Nicholson and Lindon 2008]. Other 
useful definitions have appeared in the literature [Ellis et al., 2007, Dunn et al., 2011] Table 1. 
In the particular setting of disease diagnosis it is relevant to talk about metabolic 
fingerprinting and metabonomics, both strategies aimed mainly at differentiating between 
two or more sets of data (i.e., disease/healthy) in a quantitative (metabonomics) or qualitative 
approach (fingerprinting). 
As with other 'omics' technologies metabolomics aims to measure metabolite dynamics in an 
unbiased manner; the advent of analytical and statistical methods has made possible to 
apply metabolic analysis to a wide range of applications. 'Omics' technologies allows the 
simultaneous measure of thousands of parameters from a single sample; together with new 
statistical methods able to tackle very large databases and systems or network approaches 
we should be able to extract the knowledge in order to better phenotype disease and help in 
the diagnostic process. Being able to apply all this newly found knowledge to the clinic is 
the next big challenge at the beginning of the 21st century. 
Genomics, proteomics and metabolomics are closely related approaches as they are all 
aimed at the quantitative, non-biased study of biological systems although not at the same 
level. Genomics was the first to appear, the relative chemical simplicity of DNA allowed the 
implementation of high throughput approaches first; it was followed by proteomics and 
finally metabolomics. Although there is a continuum between genomics and metabolomics 
with multiple interactions between genes, proteins and metabolites (Figure 1) the study of 
the metabolome is relevant because the it is downstream of the genome it is thereby 
amplified both in theory [Mendes et al., 1996] and in practice [Raamsdonk et al., 2001]. It has 
also been shown that small changes in the concentration of enzymes have only small effects 
on the fluxes through metabolic pathways but the changes in metabolite intermediates may 
be substantial [Cascante et al., 2002]. 
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Term Definition  
Metabolomics The nonbiased identification and quantification of all the 
metabolites present in a biological system 
Metabolome  The complete set of low-molecular-weight metabolites present 
in a biological sample (i.e., biofluid, organism, bacterial 
community) 
Metabolic profiling Identification and quantification of a selective number of 
metabolites, usually related to a specific metabolic pathway. 
Metabolic fingerprint Global, high-throughput analysis aimed at sample 
classification. Also used as a screening tool. 
Metabolic footprint Analysis of the metabolites secreted/excreted by an organism; 
it may include environmental and growth substances. 
Metabolite target analysis Qualitative and quantitative analysis of one, or several, 
metabolites related to a specific metabolic reaction. 
Metabonomics Quantitative analysis of metabolites in response of biological 
perturbations or genetic modification. 
Lipidomics Analysis of all lipids, and the molecules with they interact, and 
their function within a biological system. 
Metabolite flux analysis Also known as fluxomics. Labeled metabolites are fed into a 
biosystem and the destination of the label is assessed, usually 
in a time-dependent manner. 
Metabotype The metabolic phenotype.  
Table 1. Definitions of terms used in metabolomics. Modified from [Ellis et al 2007, 
Goodacre 2007]. 
Metabolism is downstream of the genome, transcriptome and proteome leading to an 
amplification of the signal. Only 2766 metabolites are estimated to be derived from man 
[Duarte et al., 2007], compared with 31896 genes [http://eugenes.org] and 106 different 
proteins estimated from gene expression, alternative splicing and post-translational 
modifications [Oh 2004, Goodacre 2007] makes the metabolome relatively simple. 
Also, another characteristic of the metabolome is that it is affected by disease and external 
perturbations, such as age [Fredman et al., 2004, Athertorn et al., 2009], nutrition, disease, 
gut microflora, toxins and drugs [Bollard et al., 2005]. This favours the study of the 
metabolome as a relevant representation of the phenotype [Ellis et al., 2007]. While the 
genome does provide information about the future (for example, the probability of suffering 
a disease) the metabolome reflects what is actually happening to the system (i.e. is it 
diseased? How is responding to treatment?).  
Metabolism is organized as a scale-free network [Jeong et al., 2000]. These networks are 
composed of highly interconnected nodes (metabolites) that link together the various parts 
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of the network making them are very robust against random errors [Albert et al., 2000]. 
Also, any perturbation will be rapidly and widely spread throughout the network, thus, the 
detection of a few highly interconnected nodes allows to detect differences originating in 
distant parts of the metabolic network [Brindle KM 2003] (Figure 2). The way metabolic 
networks spread perturbations allow for an easy detection but it is difficult to retrace the 
steps back to the origin unless there is some prior knowledge as in the case of the FANCY 
approach [Raamsdonk et al., 2001]. 
The properties of a system are different from those of its individual components; systems 
biology aims to study all the components of a systems and their interaction; according to 
Sauer and cols. [2007], complex biological networks are “better addressed by observing, 
through quantitative measures, multiple components simultaneously, and by rigorous data 
integration with mathematical models” [Sauer et al., 2007]. Accordingly, the integration of 
all the information obtained from the 'omics' approaches will be essential when trying to 
understand how biological networks change during disease; a new field of network analysis 
is emerging in oder to tackle the integration of various 'omics technologies and in silico 
models [Loscalzo et al., 2007].  
 
Fig. 1. Schematic representation of the interaction between different 'omes'. The metabolome 
or metabolic phenotype is both downstream of the genome, proteome and trasciptome and 
also affected by the environment including disease and drug treatments; it is thus well 
suited as a diagnostic and treatment follow-up tool. 
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Fig. 2. Organization of scale free networks, perturbations (marked here as star) in the network 
are transferred to the central hubs of metabolism (Gray circles) allowing the detection of many 
different situations even though the metabolites directly responsible for them are beyond the 
limits of technical detection. Once a change in one or more hubs is detected, knowing the 
metabolic reactions ultimately responsible for them may not be straight forward unless there is 
some prior knowledge as in the FANCY approach [Raamsdonk et al., 2001]. 
1.1 Methodologies 
The chemical diversity of metabolites has promoted the use of various analytical methods 
(Table 2), the most common ones being NMR spectroscopy and Mass spectrometry. There 
are other analytical methods including infrared, visible, and Raman spectroscopy reviewed 
elsewhere [Ellis et al., 2007]. 
Mass spectrometry operates by forming ions (positively or negatively charged) and separating 
them according to their mass to charge ratio (m/z). It is a high sensitivity method that allows 
high mass accuracy and resolution thus allowing chemical identification of metabolites; it has 
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been proposed as the real metabolomic approach [Kell 2004]. Mass spectrometer detectors are 
usually placed after a chromatography (gas or liquid) step; this introduces a bias as there will 
be some metabolites that will not be able to reach the detector. If there is prior knowledge of 
which group of metabolites may be affected the bias may turn to be an advantage and mass 
spectra the ideal tool to use as it is possible to focus interest in a group of metabolites (Figure 3A).  
NMR spectroscopy looks into magnetic properties of atomic nuclei when placed in a 
magnetic field; the molecular environment (electronic cloud) is able modify the magnetic 
field thus each nuclei within a molecule will sense a slightly different magnetic field that in 
turn allow to differentiate between them in a spectra (Figure 3B). A more detailed 
description of the applications of biological NMR spectroscopy can be found elsewhere 
[Bothwell and Griffin 2011] 
When sample classification, as in the case of disease diagnosis, is the primary objective, 
metabonomics or metabolic fingerprinting is the desired approach. In this case, NMR 
spectroscopy is the preferred analytical technique because it is fast, reproducible and cheap 
on a per-sample basis. NMR spectroscopy is only able to detect a limited number of 
metabolites but it is able to pick metabolic differences arising from very different parts of the 
metabolic network; the reason behind this lies on the fact that most of the central hubs of 
metabolic networks are 'NMR visible', by monitoring these hubs it is possible to indirectly 
detect a huge number of metabolic alterations [Griffin 2003]. 
Mass and NMR spectroscopy can be performed on easy to obtain biofluids (serum, urine, 
saliva, etc) that integrate metabolites from various processes and organs thus providing an 
integrative metabolic snapshot. 
1.2 Data analysis 
Metabolomic, and other 'omic' technical advances has been mirrored by advances in data 
processing, statistical methods able to work with large data sets comprising many more 
variables than subjects under study. The objective of the various pattern recognition 
techniques is two-fold; on the one hand they aim at classification between two or more 
groups of samples but also to extract information about which variables (metabolites) are 
relevant for each classification.  
To investigate the innate variation in a dataset, unsupervised techniques such as principal 
component analysis (PCA) [Hotellin 1933] could be used. In this approach, the sources of 
variation within the dataset are organized as orthogonal, thus independent, vectors in a 
descending manner so the first principal component (PC) is the one that explains more 
variation, followed by the second, third, etc. It is possible that the condition under study, for 
example a disease, is one of the main sources of metabolic variation; then one of the first PCs 
will be related to the effect of disease to the metabolic profile and allow for a discrimination 
between healthy and diseased samples. The great advantage of unsupervised techniques is 
that they don't require prior knowledge of the condition under study. Also, unsupervised 
approaches are useful in removing out-layers from the dataset. 
However, when unsupervised approaches are not sufficient, supervised techniques may be 
better suited to answer specific questions. These approaches require the input of the group of 
each sample in order to create a statistical model that maximizes the differences between 
groups and minimizes inter-group variation. In the case of supervised models, it is necessary 
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to test the robustness and predictability of the models produced in order to avoid creating 
models that will only fit the data used to create them. The ideal situation is when two different 
datasets are used, one to create the model and an independent one to test it; when the number 
of samples is limited, internal validation protocols like 'leave-one-out' may be used. 
 
Fig. 3. Examples of UPLC MS-MS spectra (A) from rat urine treated with phenilacelilglutamine 
where each peak corresponds to an ion and an 1H-1H COSY NMR spectra of human serum (B) 
showing the correlation between close (three bond) protons in a molecule. 
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1.3 Metabolic profiling 
Sample classification is one of the main targets of any 'omics' technology, when the groups 
of samples include a healty (control) and at least one diseased group (case) the method can 
be used directly as a diagnostic tool. 
Metabolite levels, at least some of them, change between healthy and diseased states and 
may respond to therapeutic intervention (Figure 4). Perturbations in the metabolic pathways 
may occur prior to clinical symptoms, those would be the early prognostic markers. It is 
likely that at the early stage of disease a few metabolites may be slightly altered but not far 
away from normal values; in this case fingerprinting (Figure 5A), measuring a variety of 
metabolites, may be the tool to use in order to detect early markers of diagnosis. On the 
other hand, as a disease progresses it is more likely that one (or more) metabolites alter their 
concentration significantly, consequently looking for individual metabolites associated to a 
disease may be the better choice.  
 
Fig. 4. Metabolite levels during disease evolution. In the pre-clinical stage some metabolites 
may be altered but likely within the normal deviation of the population, in this setting 
metabolic profiling of various metabolites may be a good approach towards finding 
discriminant models; on the other hand in the clinical stages it is possible that one or a few 
metabolites are highly modified from their normal values in this case looking for biomarkers 
would be relevant. Some metabolites may change after treatment allowing for unbiased 
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1.4 Biomarker discovery 
On top of sample classification, metabolomic analysis is able to provide information 
regarding which metabolites are more relevant for a classification. It is thus possible to 
identify individual metabolites that could be used as biomarkers and use metabolomic 
analysis can be used as a tool for biomarker discovery. Once a metabolite is identified 
(Figure 5A) as a biomarker using high throughoutput metabolomic methodologies it may be 
detected by classical analytical methods for clinical practice. For example, Sreekumar and 
cols. [2009] were able to identify sarcosine in urine as potentially important metabolic 
intermediary of cancer cell invasion and aggressiveness after profiling 1126 metabolites 
from 262 clinical samples. 
 
Fig. 5. Metabolomics in clinical applications. Panel A shows the result of a discriminant 
analysis of NMR spectra from serum obtained from patients in the coronary unit and 
healthy controls. Circles correspond to 95% confidence intervals. Note that dispersion in 
samples from patients is higher that that of controls. Pattern recognition analysis allows to 
identify the most relevant variables in an analysis and it is possible to identify the 
metabolite responsible. Panel B shows a 1H-13C HSQC NMR spectra; a useful approach to 
identify metabolites. Processing shown in panel A was obtained using Metaboanalyst 
software [Xia et al., 2009]. 
Once a variable in the analysis is found to be relevant in a classification model it can be 
associated to a metabolite because mass to charge ratio and chemical shift are specific  
for each metabolite. There are public databases that help metabolite identification 
http://www.hmdb.ca/. In order to obtain an absolute identification, though, it is important 
to perform co-resonance or co-elution experiments. 
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Figure 6 shows a typical metabolomic experimental design aimed at disease diagnosis. 
Metabolic profiling and biomarker discovery are not excluding strategies; moreover there is 
a synergy between them and also with the use of metabolic and pathway information that 
are not directly associated to diagnostic applications.  
 
Fig. 6. Typical work-flow in a metabolomic study aimed at disease diagnosis. Once the 
database is obtained, supervised and unsupervised statistical methods are applied to obtain 
discriminant models that could be applied directly in the clinic or to find biomarkers. The 
future of metabolomics will be the implementation of information obtained at different 
stages of the analysis, particularly relating to metabolites and metabolic pathways into 
systems biology approaches. 
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2. Metabolomic applications in cardiovascular diseases 
2.1 Basic research applications/metabolic phenotyping 
Metabolic analysis has been widely used in laboratory research applications. One of the 
main uses in this field was the metabolic phenotyping of mouse models of cardiovascular 
diseases; this approach was pioneered by the group of Julian Griffin mainly using models of 
Duchenne muscular distrophy where they were able to show different metabolic profiles 
associated with the expression of dystrophin and utrophin in heart muscle [Griffin et al., 
2002, Griffin and Des Rosiers 2009]. In a later work the same group applied the FANCY 
approach (Functional Analysis by Co-responses in Yeast) to mouse models of cardiac 
diseases and showed that although the background strain of mice was an important source 
of metabolic variation, multivariate statistics were able to separate each disease model from 
the control strain [Jones et al., 2005].  
Another mouse model well characterized form the metabolic point of view is the PPAR- 
null mouse where authors demonstrate that age exacerbates the changes associated with 
genotype in this mouse model lacking the peroxisome proliferator activated receptor-a 
[Athertorn et al., 2009]. Recent reports describing the phenotype of genetically modified 
mouse models tend to include data regarding the metabolism [Inserte et al., 2009, 
Rodriguez-Sinovas et al., 2010, Ashrafian et al., 2010]. This is a trend that will become 
increasingly popular as it becomes clear that the the metabotype is a relevant part of the 
phenotype. 
In 2003 a method to hyperpolarize 13C and increase the signal to noise ratio 10000 times was 
described [Ardenkjaer-Larsen et al., 2003], this opened the possibility of following 
metabolism in vivo through 13C NMR spectroscopy. It has been possible to measure energy 
production, particularly the Krebs cycle turnover, by following the label in 1-13C-pyruvate 
[Golman et al., 2008, Schroeder et al., 2009, 2010] in animal models. Also, pH can be 
monitored in vivo by measuring hyperpolarised bicarbonate signals [Gallagher et al., 2008, 
Schroeder et al., 2010]. This extremely sensitive method may play a great role in clinical 
practice, specially in heart failure where metabolism and its modification through medical 
treatment is relevant [Lee et al., 2005, Abozguia et al., 2006] 
Because NMR is non-invasive, there is the possibility of obtaining localized spectra. While 
this is technically feasible in brain [Sundgren et al., 2009] it is more complex in the case of 
heart due mainly to cardio-respiratory motion. However, we were able to differentiate 
between necrotic, at risk and control areas in an animal model using high resolution magic 
angle spinning NMR (HR-MAS) [Barba et al., 2007], in consequence, if chemical shift 
imaging becomes feasible it would be possible to necrosis and at risk areas after myocardial 
infarction.  
2.2 Treatement monitoring and follow up 
One of the key areas of metabolomics application is treatment monitoring and follow-up; 
actually the term metabonomics was introduced by Nicholson and cols [Nicholson et al., 
1999] as a toxicology tool to evaluate the effect of drugs. A decade later the same authors 
have introduced the term 'pharmacometabonomics' in drug treatment defined as an 
approach “which uses metabolite profiling and chemometrics to model and predict 
responses of individual subjects” [Clayton et al., 2006, Nicholson et al., 2011] 
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A great variety of studies have been published in the literature, mostly in the field of cancer 
[Spratlin et al., 2009]. But in the area of cardiovascular diseases the amount of reports has 
been very limited, possibly associated to the few new drug treatments appearing for 
cardiovascular diseases as compared to, for example, cancer.  
So far, reports regarding heart disease and drug treatments in the literature are focused on 
animal models either studying drug toxicity [Perrine et al., 2009, Andreadou et al., 2009] or 
the effect of antioxidant intervention [Constantinou et al., 2009]. This relative lack of reports 
may be due to the fact that the number of new drugs under development in the 
cardiovascular area is not as high as in other fields such as oncology. 
2.3 Clinical application of metabolomics 
Since the beginning of the 21st century the term 'personalized medicine' has continuously 
gained popularity and is now considered an essential trait of present and future medicine. 
For personalized medicine to be successful, it is necessary to properly identify subjects at 
increased risk of developing a disease, which patients will respond to a given therapy or 
how a disease will evolve in each case. In other words it is important to genotype and or 
phenotype the individual patient so that its individual response to disease and treatment 
can be predicted. 
Metabolomics is a promising technology for personalized medicine, it is fast, reproducible, 
easy to automate and not very expensive on a per sample basis. Most important, unlike the 
genome, the metabolome is modified by external factors such as disease. Today the only 
field where personalized medicine is flourishing is cancer; by definition cancer does imply 
modifications of the genome and genomics is technically more advanced than 
metabolomics. For diseases that does not imply the modification of the genome, such as 
cardiovascular pathology, metabolomics may be the tool of choice and extensive research 
has been conducted in recent years towards achieving this goal.  
In 2002, Brindle and cols. published a paper in which they describe ”a techniques capable of 
providing an accurate, noninvasive and rapid diagnosis of coronary heart disease” [Brindle 
et al., 2002]. 1H NMR spectra from serum samples from patients diagnosed with no coronary 
artery disease or with one, two or three vessel disease was used to create discriminant 
models able to differentiate the severity of coronary artery disease. Unfortunately, the 
authors did not take into account the effects of medical treatments (particularly statins) and 
patient gender in their analysis and was later demonstrated that those two factors have a 
strong influence in the NMR pattern. As a result, the specificity and sensitivity first 
predicted of above 90% was reduced, once corrected by gender and statin use to 
approximately 60% [Kirschenlohr et al., 2006]. Also, age has also been described as a 
differential factor regarding lipoprotein subclasses measured by NMR spectroscopy 
[Freedman 2004]. Nevertheless, the paper by Brindle and cols [Brindle et al., 2002] has been 
extremely important in the field because it quick started pre-clinical metabolomic studies. 
Sabatine and cols [Sabatine et al., 2005] showed that it was possible to apply metabolomic 
analysis in a carefully characterized cohort of patients undergoing exercise stress testing 
and to differentiate between patients that developed inducible ischemia from the ones 
that did not [Sabatine et al., 2005]. This work was done by analyzing serum samples 
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obtained before, during and after stress testing by high performance liquid 
chromatography coupled to mass spectroscopy; ischaemic patients had higher circulating 
levels of metabolites belonging to the citric acid pathway. Later, we were able to show 
that it was possible to predict which patients would suffer from a positive stress test by 
analyzing serum samples obtained before the stress test using 1H NMR spectroscopy 
[Barba et al., 2008]. Ischemic patients had relatively higher lactate levels than non 
ischemic suggesting an underlying ischemic process although it could not be directly 
related to myocardial ischemia. Differences between the two groups were seen in samples 
obtained prior to the stress test thus, at least in theory, it would be possible to use 
metabolic profiling instead of stress testing but, unfortunately, the accuracy of the 
predictions was around 85%, clearly not high enough as to be used in the clinical setting. 
Searching for early markers of ischemia, Lewis and cols [Lewis et al., 2008] studied 
patients undergoing planed alcohol septal ablation and were able to detect several 
metabolites that changed early after myocardial injury and report a ROC curve for a 
composite metabolite score with an area under the curve of 0,88 ± 0,07. 
It has been known for a time that patients with heart failure (HF) have an altered heart 
metabolism [Clark et al., 1996] and that metabolic modulation (shifting the main substrate 
from free fatty acids to glucose) improved VO2max, left ventricular ejection fraction, 
symptoms, resting and peak stress myocardial function, and skeletal muscle energetics [Lee 
et al., 2005]. Metabolic modulation as a tool to treat patients with heart failure has attracted 
interest [Abozguia et al., 2006] but the metabolomic analysis has not followed suit until 
recently when Kang and cols showed by profiling urine by NMR spectroscopy that it was 
possible to detect changes between HF patients and controls [Kang et al., 2011]. It could be 
interesting to evaluate possible changes in the urine metabolic profile of patients treated 
with drugs targeting heart metabolism for example, perhexiline or trimetazidine. 
Metabolomics have been used to study diseases related to the cardiovascular system like 
diabetes [Wang et al., 2011], and obesity [van de Woestinje et al., 2011] reviewed in [Griffin 
and Nichols 2006, Muller 2010] but this is beyond the scope of the present work.  
3. Future directions 
3.1 Next hurdles before clinical application 
There has been interest to apply metabolomic analysis to the clinical setting and it has been 
shown in the literature that various cardiovascular-related pathologies could be 
differentiated using metabolic analysis [Lee et al., 2005, Lewis et al., 2008, Barba et al., 2008, 
Kang et al., 2011] but there is still some work to be done for metabolomics in order 
becoming a clinical reality. 
There are two main problems to solve before metabolomics becomes a widespread clinical 
reality; the first is to make metabolomics technically easy from both data acquisition and 
processing point of view as to be used in daily routine by non-specialists. The second 
problem will be more difficult to solve and it relates to population variation; so far studies 
have focused in small, controlled populations; studies with large cohorts of patients are not 
yet present in the literature. 
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Technical problems will be solved soon, there are new advances in automation procedures, 
mainly in the NMR field, that will allow to use metabolomics routinely for screening 
purposes in the near future. Moreover, once metabolic biomarkers are found using any of 
the hypothesis free metabolomics approaches their detection may be done using standard 
analytical methodologies already implemented in the clinical laboratory; in this case the 
application of metabolomics derived results would be straight forward.  
Solving problems related to population variability is much more challenging; first of all 
'omics' data processing is focused on finding sources of variation that can be later correlated 
with disease, treatment response, etc. Adding sources of variation to the dataset makes it 
difficult to identify specific patterns. Studies at population level should provide evidence for 
the background variation in metabolic profile and, thus tell how well metabolomics can 
perform in the clinical setting. 
One of the areas where the application of metabolomics may become a reality soon is the 
evaluation of response to pharmacologic treatment. Although this is one of the first areas 
were metabolomics were applied, in the case of cardiovascular diseases so far it has only 
been reported in animal studies (see above). Still, it has been show that drugs do influence 
the metabolic pattern in human studies of plasma [Kirschenlohr et al., 2006] and that 
altering metabolism could be a therapeutic target [Lee et al., 2005] thus paharmacogenomics 
application may not be far away in the area of cardiovascular disease.  
Work has started in the integration of various 'omics' technologies in global systems biology 
approaches [Mayr et al., 2007, 2008, 2009a, 2009b. Wheelock et al., 2009, De Souza et al., 
2010]. Systems biology should provide with a complete and definitive view of a biomedical 
problem [Barabasi et al., 2011] but there are some problems associated that need to be 
solved. For example, just to integrate all the data it has to be considered that response time 
after a stimulus is not the same in transcripts, proteins or metabolites. Also, fold change in 
metabolite levels does not have to mimic changes in mRNA or protein levels.  
4. Conclusion 
In conclusion, the future of metabolomics is now. It is clear that metabolomics can be 
applied to various cardiovascular related diseases, although its clinical value in different 
settings remains to be determined; this is the next big challenge in the field. 
Metabolomics, being a high throughput methodology is very well suited for biomarker 
discovery. The detection of biomolecules is an established methodology in the everyday 
clinical practice thus once a new biomarker has been found its application to the clinic 
should be straight forward. In our opinion, this approach will be successful in the sort term 
if it is able to address specific and relevant clinical situations. 
Also, efforts should focus on the integration of metabolomics with systems biology analysis 
as in the long term, for the success of personalized medicine, the treatment of diseases will 
give way to the treatment of patients each with individual co-morbidities and environment. 
How well the integration of systems biology is archived will define the future not only of 
metabolomics but of all the 'omics' approaches. 
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